Modi faces stunning electoral defeat in stronghold state

In a significant political shift, Prime Minister Narendra Modi's party has suffered a major defeat in Uttar Pradesh, a state that has long been considered a stronghold for him. The recent election results revealed that Modi's party lost over half of its seats in the region, including the district where he inaugurated a grand temple on the site of a demolished mosque earlier this year. This outcome is seen as a reflection of the broader discontent with Modi's decade-long rule, which has been marked by increasing violence against religious minorities and a crackdown on civil liberties.

Political analysts suggest that this defeat could weaken Modi's leadership, making him more reliant on coalition partners. This shift may lead to a resurgence of civil society voices that have been suppressed in recent years. Observers note that the partnership between India and the United States remains strong, driven by mutual interests, particularly in countering China's influence in Asia. Regardless of the political landscape in India, U.S. administrations are expected to continue collaborating with India on strategic matters.

In a separate development, an FDA advisory committee has rejected the use of MDMA, commonly known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD). The committee raised concerns about the effectiveness of the drug, which was part of a treatment regimen that included psychotherapy. They highlighted issues such as the lack of standardized therapy and the inability to properly blind participants in the trials, which compromised the objectivity of the results.

Despite the committee's decision, many patients and researchers had hoped for approval, citing transformative experiences with the drug. The committee's vote was notably divided, with a 9 to 2 decision against the treatment's efficacy and a 10 to 1 vote indicating inadequate safety measures during trials. The FDA will now consider the committee's recommendations before making a final decision, expected around August 11. The outcome is particularly significant for veterans, as there is bipartisan congressional support advocating for further studies into MDMA's potential benefits for PTSD treatment.